Correlation between pretransplantation test dose cyclosporine pharmacokinetic profiles and posttransplantation sirolimus blood levels in renal transplant recipients

Therapeutic Drug Monitoring

Volumn 21, Issue 1, 1999, Pages 44-49

  Kaplan, Bruce ^a   Meier Kriesche, Herwig Ulf ^a   Napoli, Kimberly L ^a   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cyclosporine; Pharmacokinetics; Rapamycin; Renal; Sirolimus

Indexed keywords

CYCLOSPORIN A; PREDNISONE; RAPAMYCIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; ORAL DRUG ADMINISTRATION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL;

BIOLOGICAL AVAILABILITY; COHORT STUDIES; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; METABOLIC CLEARANCE RATE; PREOPERATIVE CARE; SIROLIMUS;

EID: 0033055755     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199902000-00007     Document Type: Article

References (33)

1. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22.989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 1975;2812:721-6.
2. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22.989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot 1975;28:727-32.
3. Calne RY, Collier DS, Lim S, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989;2:227.
4. Kahan BD, Chang JY, Sehgal SN. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 1991;52:185-91.
5. Fryer J, Yatscoff RW, Pascoe EA. et al. The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model. Transplantation 1993;55:340-5.
6. Ochiai T, Gunji Y, Nagata M, et al. Effects of rapamycin in experimental organ allografting. Transplantation 1993;56:15-9.
7. Granger DK, Cromwell JW, Chen SC, et al. Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. Transplantation 1995;59:183-6.
8. Zimmerman J, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997;37:405-15.
9. Sattler M, Guengerich FP, Yun CH, et al. Cytochrome p-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-61.
10. Kahan BD, Welsh M, Rutzky L. et al. The ability of pretransplantation test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation. Transplantation 1992;53:345-51.
11. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes p-450. Studies in rats and patients. J Clin Invest 1989;83:688-97.
12. Watkins PB, Hamilton TA, Annesley TM, et al. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 1990;48:120-9.
13. Turgeon DK, Normolle DP, Leichtman AB, et al. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther 1992;52:471-8.
14. Turgeon DK, Leichtman AB, Blake DS, et al. Prediction of interpatient and intrapatient variation in OG 37-325 dosing requirements by the erythromycin breath test. Transplantation 1994;57: 1736-41.
15. Napoli KL, Kahan BD. Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations. J Chromatogr B Biomed Appl 1994;654:111-20.
16. Ritschel WA. Handbook of basic pharmacokinetics. Hamilton. IL: Drug Intelligence Publications, 1992:356.
17. Kahan BD, Welsh M, Rutzky LP. Challenges in cyclosporine therapy: The role of therapeutic drug monitoring by area under the curve monitoring. Ther Drug Monit 1995;17:621-4.
18. Browne B, Kahan BD. Renal transplantation. In: Kahan BD, ed. Surgical clinics of north America. Philadelphia; WB Saunders, 1994:1097-116.
19. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993;54:205-18.
20. Norusis MJ. SPSS for Windows users guide. Chicago: SPSS Inc., 1993:311.
21. Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996;49:209-16.
22. Kahan BD. Sirolimus: A new agent for clinical renal transplantation. Transplant Proc 1997;29:48-50.
23. Grevel J, Kahan BD. Area under the curve monitoring of cyclosporine therapy: The early posttransplant period. Ther Drug Monit 1991;13:89-95.
24. Lindholm A, Welsh M, Alton C, et al. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability. Clin Pharmacol Ther 1992;52:359-71.
25. Lindholm A, Welsh M, Rutzky L, et al. The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss. Transplantation 1993;55:985-93.
26. Bonkovsky HL, Hauri HP, Marti U, et al. Cytochrome p450 of small intestinal epithelial cells. Immunochemical characterization of the increase in cytochrome p450 caused by phenobarbital. Gastroenterology 1985;88:458-67.
27. Kaminsky LS, Fasco MJ. Small intestinal cytochromes p450. Crit Rev Toxicol 1991;21:407-22.
28. Christians U, Sewing KF. Cyclosporin metabolism in transplant patients. Pharmacol Ther 1993;57:291-345.
29. Christians U, Bleck JS, Lampen A, et al. Are cytochrome P450 3A enzymes in the small intestine responsible for different cyclosporine metabolite patterns in stable male and female renal allograft recipients after co-administration of diltiazem? Transplant Proc 1996; 28:2159-61.
30. Gomez DY, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-9.
31. Wu CY, Benet LZ, Hebert MF, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine. Clin Pharmacol Ther 1995;58:492-7.
32. Chang T, Benet LZ, Hebert MF. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 1996;59:297-303.
33. Yacyshyn BR, Bowen-Yacyshyn MB, Pilarski LM. Inhibition by rapamycin of p-glycoprotein 170-mediated export from normal lymphocytes. Scand J Immunol 1996;43:449-55.